Longevity-focused health management platform Function Health has partnered with GRAIL, Inc., a healthcare company focusing on early cancer detection and treatment, to expand access to revolutionary cancer screening.
As reported earlier by HIT, the partnership allows over 400,000 Function Health customers access to GRAIL’s first-of-its-kind test called the Galleri test. The multi-cancer early detection (MCED) test is designed to screen for many types of cancers from just a single blood draw, adding to the company’s list of over 100 lab tests.
Transforming Cancer Care Through Advanced Testing
Cancer is one of the leading causes of death in the United States. In 2024, new cancer infections are expected to exceed 2 million, with 611,172 potential deaths, according to the National Cancer Institute. However, more than 70% of these deaths result from some types of cancers that currently do not have the recommended tests.
Focusing on providing over 100 comprehensive lab tests for various illnesses, Function aims to transform cancer care by allowing its users access to the Galleri test. This early cancer diagnostic tool can detect up to 50 cancer types from a single blood sample, including esophageal, ovarian, pancreatic, and liver cancer, which currently have no standard tests.
According to Dr. Mark Hyman, Co-Founder and CEO of Function Health, the new integration will allow the company to offer Galleri tests among its lab tests, allowing their members to screen for cancer during their annual checkups. This would enhance patients’ treatment options and outcomes, he added.
